Zhitong Finance App News, Hehuang Pharmaceutical (00013) issued an announcement. Following the medical insurance renewal with China's National Health Insurance Administration (NHS), ELUNATE® (ELUNATE®), ORPATHYS® (ORPATYS®), and SULANDA® (SULANDA®) will continue to be included in the new “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue” (National Medical Insurance Drug Catalogue) effective from January 1, 2027. This update covers the inclusion of new indications, renewal of existing indications, and ongoing coverage under the current multi-year agreement.
Indications newly included and renewed in the new National Medicare Drug Catalogue: • Elute® (fruquintinib) has been included in combination with sintilimab injection (sintilimab injection) to treat patients with locally advanced or metastatic renal cell carcinoma who have previously failed vascular endothelial growth factor receptor (VEGFR) -tyrosine kinase inhibitors (TKI) and did not receive programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibitors on the frontline. • Vorexa® (savolitinib) was included in combination with osimertinib (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with MET amplification that progresses after EGFR-TKI treatment with positive epidermal growth factor receptor (EGFR) gene mutation. Indications for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer carrying the interstitial to epithelial conversion factor (MET) exon 14 jump have also been renewed.
In addition to the above updates, based on the current multi-year agreement, the national medical insurance drug catalogue will continue to cover all other indications previously included in Elliot®, Warisa®, and Suteida®.
The Chinese government attaches great importance to improving the affordability of people's medication. By the end of 2025, the number of people enrolled in basic medical insurance in China was 1.33 billion, and the participation rate had stabilized at around 95%. The national medical insurance drug catalogue is adjusted every year, and drugs included in the catalogue are renewed every two years. Every year, the National Health Insurance Administration convenes an extensive network of experts, including medical experts, pharmacy experts, pharmacoeconomics experts, and fund estimation experts, to update and adjust the entry of innovative drugs into the national medical insurance drug catalogue. Reimbursement for Class B drugs (including innovative oncology drugs) requires patients to pay different percentages of deductibles according to their province of residence or the type of health insurance they participate in.